Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Akihiko Miyanaga, MD, PhD"'
Autor:
Takehiro Tozuka, MD, Rintaro Noro, MD, PhD, Keisuke Yoshida, PhD, Satoshi Takahashi, MD, PhD, Mariko Hirao, MD, Kuniko Matsuda, MD, Yasuhiro Kato, MD, Shinji Nakamichi, MD, PhD, Susumu Takeuchi, MD, PhD, Masaru Matsumoto, MD, PhD, Akihiko Miyanaga, MD, PhD, Shinobu Kunugi, MD, PhD, Kazufumi Honda, DDS, PhD, Jun Adachi, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100668- (2024)
Introduction: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non
Externí odkaz:
https://doaj.org/article/28ffabd2f77f47d7942680f03c8b460c
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Autor:
Yuto Terashima, MD, Masaru Matsumoto, MD, PhD, Hiroki Iida, MD, Sae Takashima, MD, Aya Fukuizumi, MD, PhD, Susumu Takeuchi, MD, PhD, Akihiko Miyanaga, MD, PhD, Yasuhiro Terasaki, MD, PhD, Kazuo Kasahara, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100578- (2023)
Introduction: Pervious studies reported the association of TTF-1 expression with the efficacy of platinum-doublet chemotherapy in combination with immune checkpoint inhibitors in advanced nonsquamous NSCLC. Nevertheless, the predictive value of exten
Externí odkaz:
https://doaj.org/article/a8d24f9941d1407ebf190954c5f35839
Autor:
Aya Fukuizumi, MD, Rintaro Noro, MD, PhD, Masahiro Seike, MD, PhD, Akihiko Miyanaga, MD, PhD, Yuji Minegishi, MD, PhD, Miwako Omori, MD, Mamiko Hirao, Kuniko Matsuda, Shinobu Kunugi, MD, PhD, Kazutaka Nishiwaki, Masahiro Morimoto, Haruka Motohashi, Hayato Ohwada, PhD, Jitsuo Usuda, MD, PhD, Akihiko Gemma, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100232- (2021)
Introduction: To investigate the genomic profiles of patients with lung cancer with idiopathic pulmonary fibrosis (IPF-LC), mechanism of carcinogenesis, and potential therapeutic targets. Methods: We analyzed 29 matched, surgically resected, cancerou
Externí odkaz:
https://doaj.org/article/790906db2fa7483283e2b97f1365bd03